How many institutional investors hold DNTH?

2 tracked institutional investors disclosed a position in DNTH (DIANTHUS THERAPEUTICS INC) in their most recent 13F filing.

Who is the largest institutional holder of DNTH?

Ken Griffin, Citadel Advisors, holds the largest disclosed position in DNTH, valued at $138M.

Where does this DNTH ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

DNTH — DIANTHUS THERAPEUTICS INC

Name: DIANTHUS THERAPEUTICS INC (DNTH) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Public company

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying DNTH?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence

Institutional Conviction

Strong distribution · 0 buying vs 1 selling last quarter

Macro Tailwind

Macro conditions are mixed for this sector

Why? — Evidence & Confidence ▾

Of 1 tracked investors who changed their DNTH position last quarter, 0 bought and 1 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime).

Supporting evidence

+2 tracked investors reported holding DNTH at their latest filing
+Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource

Contradicting evidence — always shown

−1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
−13F data is disclosed up to 45 days after quarter end — positions may have changed since

Know the limits

· 13F disclosure lag (up to 45 days)
· Tracked investors are a sample, not the whole market
· Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About DIANTHUS THERAPEUTICS INC (DNTH)

DIANTHUS THERAPEUTICS INC (DNTH) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $138M. Across recent filings, tracked investors recorded 1 new positions, 3 increased, 4 reduced, and 1 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in DNTH

/100

Mixed Activity

Added / Increased4

Reduced4

Exited1

BearishBullish

Crowded Trade Score™

How many top investors track DNTH

/100

Undiscovered

2investors

Only 2 tracked investors report this position.

UndiscoveredCrowded

151015+

DNTH Ownership Composition

How DIANTHUS THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type

Multi-Strategy / Quant

100% of tracked value

Institutions

tracked investors

Total Reported

$109M

combined 13F value

Multi-Strategy / Quant100.0%

Multi-Strategy / Quant(2)

100.0%

Tracked investors currently reporting DNTH

1 tracked investor has since exited this position — listed separately below.

Investor	Firm	Shares	Market value	% of portfolio	As of
Ken Griffin	Citadel Advisors	1M	$100M	0.01%	Jun 30, 2026
Izzy Englander	Millennium Management	91.8K	$9M	0.00%	Jun 30, 2026

Ken GriffinJun 30, 2026
Citadel Advisors
Shares
1M
Value
$100M
% Portfolio
0.01%
Izzy EnglanderJun 30, 2026
Millennium Management
Shares
91.8K
Value
$9M
% Portfolio
0.00%

Previously held DNTH

These investors reported DNTH in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

Investor	Firm	Last reported shares	Value then	Last held
Steve Cohen	Point72 Asset Management	643.6K	$54M	Mar 31, 2026

Recent activity

Investor	Action	Δ %	Current value	Filing date
Steve Cohen	Increased	151.26%	$12M	Nov 14, 2024
Steve Cohen	Reduced	-55.77%	$4.2M	Feb 14, 2025
Steve Cohen	Increased	668.05%	$27M	Jul 21, 2025
Steve Cohen	Reduced	-6.35%	$25.9M	Aug 14, 2025
Steve Cohen	Increased	46.64%	$80.4M	Nov 14, 2025
Steve Cohen	Reduced	-42.89%	$48.1M	Feb 17, 2026
Steve Cohen	Reduced	-44.81%	$54M	May 15, 2026
Steve Cohen	Sold	-100.00%	$0	Aug 14, 2026
Steve Cohen	New	—	$4.5M	Sep 16, 2024

Steve Cohen
Increased
$12M(151.26%)Nov 14, 2024
Steve Cohen
Reduced
$4.2M(-55.77%)Feb 14, 2025
Steve Cohen
Increased
$27M(668.05%)Jul 21, 2025
Steve Cohen
Reduced
$25.9M(-6.35%)Aug 14, 2025
Steve Cohen
Increased
$80.4M(46.64%)Nov 14, 2025
Steve Cohen
Reduced
$48.1M(-42.89%)Feb 17, 2026
Steve Cohen
Reduced
$54M(-44.81%)May 15, 2026
Steve Cohen
Sold
$0(-100.00%)Aug 14, 2026
Steve Cohen
New
$4.5MSep 16, 2024

Frequently asked questions

How many institutional investors hold DNTH?: 2 tracked institutional investors disclosed a position in DNTH (DIANTHUS THERAPEUTICS INC) in their most recent 13F filing.
Who is the largest institutional holder of DNTH?: Ken Griffin, Citadel Advisors, holds the largest disclosed position in DNTH, valued at $138M.
Did institutional ownership of DNTH increase or decrease?: Across recent 13F filings, tracked investors recorded 1 new positions, 3 increased, 4 reduced, and 1 fully exited DNTH.
Where does this DNTH ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.